“In reality, you’re seeing nothing but good data come out of the CRISPR space. I don’t believe the ability to cure patients is going anywhere.” – @benjaminloakes.bsky.social, Scribe CEO in GEN on delivering the full promise of #CRISPR Read more here and our 🧵: www.genengnews.com/topics/genom...

We’re pleased to announce the achievement of a success milestone in our collaboration with Prevail Therapeutics, a part of @elilillyandcompany.bsky.social’s Gene Therapy Division, to develop in vivo #CRISPR-based therapeutics for neurological and neuromuscular disorders. Highlights below 🧵

The future of medicine is bright — and it’s going to look radically different from today. It’ll be: 🧬 Preventive ⚡ Liberating 🌍 Universal This isn’t science fiction — it’s what we’re building at @ScribeRx. Let me break it down 👇

#LpaAwarenessDay Cardiovascular disease is the leading cause of death worldwide, claiming 18 million lives each year. Did you know that 1 in 5 people have high levels of Lp(a) or lipoprotein(a), which significantly increases the risk of heart disease?

This week, I’ll highlight two recent CRISPR advances: 1) BEAM’s exciting Phase 1 clinical data for BEAM-302. 2) Impressive work from the labs of Scribe’s co-founders @savagecatsonly.bsky.social & @doudna-lab.bsky.social —providing a textbook example of engineering CRISPR enzymes from zero to hero.

From an interview with our CEO @benjaminloakes.bsky.social, PharmaVoice spotlighted our work engineering #CRISPR genome editing and epigenetic silencing platforms to target cardiometabolic disease. Read the story about our lead asset and progress: www.pharmavoice.com/news/crispr-...

Don’t miss @jdfev.bsky.social's late-breaking talk at @keystonesymposia.bsky.social today! 📣 Symposia Spotlight 🪧 Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates 🕒 3:00-4:30 p.m. GMT 📍 INEC Main Auditorium

🧬 In the near future, my hope is that we can all win the genetic lottery for health—not by chance, but by design. At Scribe, we’re focused on making genetic medicines safe enough for disease prevention at scale and moving beyond gene editing into epigenetic editing.

As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this. Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.

As someone with close family affected by ASCVD—and therefore at high risk myself—this mission is personal, urgent and real. We will solve this. Explore our vision for the future of ASCVD treatment—and, more importantly, prevention—below.

Trying something new—highlighting research that I find enjoyable or useful in CRISPR, molecular engineering, and cardiometabolic disease. To kick things off, here are two new papers: A clever single-cell off-target method and an exploration of how Prime Editors modify global DNA repair

Check it out—we gave our website a fresh new look! 🔥 Like our CRISPR by Design™ approach, this redesign is all about precision and continuous improvement. Whether pushing the boundaries of genetic medicine or refining how we share our work, one thing never changes: at Scribe, the details matter.